Entero Therapeutics (ENTO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ENTO Entero Therapeutics

Watchlist

0.455
-0.011-2.30%

Close Nov 27 16:00 ET

0.463
+0.009+1.87%

Post 20:01 ET

2.16MMarket Cap0.03P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Entero Therapeutics Inc: Exploring Strategic Alternatives for Purpose of Maximizing Value of All of Our Stakeholders
Reuters17:14 ET
Express News | Entero Therapeutics Inc: Have Reduced Headcount and Paused Development Activities
Reuters17:14 ET
Express News | Entero Therapeutics Inc: Acceleration or Reduction of Cash Outflows and Debt Obligations Can Significantly Impact Our Ability to Maintain Operations
Reuters17:13 ET
Express News | Entero Therapeutics: On Nov 21, Immunogenx Received Notice of Default, Demand for Payment Relating to Credit Agreement, Dated as of Oct 3, 2022
Reuters17:09 ET
Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum
Yahoo FinanceNov 14 08:00 ET
Shareholder Alert: Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Business WireNov 13 21:45 ET

Comments

Jaguar8

Nov 13 06:01

NEWS

$Entero Therapeutics (ENTO.US)$
Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company
• Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey's next-gen, first-in-class ADC-rivalling, nano-immunoconjugates ("NIC") platform and therapeutic products for unmet medical needs in oncology and autoimmu...